Deutsche Bank
LRMR icon

Deutsche Bank’s Larimar Therapeutics LRMR Stock Holding History

Deutsche Bank’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$294K Buy
96,423
+3,291
+4% +$13.1K ﹤0.01% 3048
2026
Q1 		$419K Buy
93,132
+58,742
+171% +$235K ﹤0.01% 2668
2025
Q4 		$131K Sell
34,390
-20,611
-37% -$80.2K ﹤0.01% 3208
2025
Q3 		$178K Buy
55,001
+15,970
+41% +$59.9K ﹤0.01% 3118
2025
Q2 		$113K Sell
39,031
-1,006
-3% -$2.33K ﹤0.01% 3208
2025
Q1 		$86.1K Sell
40,037
-4,015
-9% -$12.7K ﹤0.01% 3242
2024
Q4 		$170K Sell
44,052
-238,010
-84% -$1.57M ﹤0.01% 3139
2024
Q3 		$1.85M Buy
282,062
+7,486
+3% +$60.2K ﹤0.01% 1799
2024
Q2 		$1.99M Buy
274,576
+2,652
+1% +$20.3K ﹤0.01% 1637
2024
Q1 		$2.06M Sell
271,924
-449
-0.2% -$3.5K ﹤0.01% 1642
2023
Q4 		$1.24M Buy
+272,373
New +$919K ﹤0.01% 1905
2023
Q3 		– Sell
-255,593
Closed -$800K – 3770
2023
Q2 		$800K Hold
255,593
– – ﹤0.01% 2103
2023
Q1 		$1.16M Buy
+255,593
New +$1.34M ﹤0.01% 2000
2020
Q1 		– Sell
-1,468
Closed -$19K – 4601
2019
Q4 		$19K Sell
1,468
-2,945
-67% -$28.1K ﹤0.01% 4315
2019
Q3 		$39K Sell
4,413
-33,792
-88% -$371K ﹤0.01% 4060
2019
Q2 		$545K Buy
38,205
+14,050
+58% +$374K ﹤0.01% 3231
2019
Q1 		$792K Buy
24,155
+15,825
+190% +$811K ﹤0.01% 3146
2018
Q4 		$494K Sell
8,330
-5,472
-40% -$540K ﹤0.01% 3337
2018
Q3 		$1.94M Buy
13,802
+5,726
+71% +$695K ﹤0.01% 2885
2018
Q2 		$992K Buy
8,076
+6,350
+368% +$539K ﹤0.01% 3430
2018
Q1 		$154K Sell
1,726
-16,808
-91% -$1.42M ﹤0.01% 4319
2017
Q4 		$1.03M Sell
18,534
-12,886
-41% -$581K ﹤0.01% 3175
2017
Q3 		$1.33M Buy
31,420
+5,593
+22% +$233K ﹤0.01% 2813
2017
Q2 		$1.09M Buy
25,827
+10,496
+68% +$537K ﹤0.01% 2978
2017
Q1 		$855K Buy
15,331
+10,836
+241% +$538K ﹤0.01% 2758
2016
Q4 		$170K Buy
4,495
+373
+9% +$15.1K ﹤0.01% 3775
2016
Q3 		$162K Sell
4,122
-13,168
-76% -$598K ﹤0.01% 3749
2016
Q2 		$1.24M Buy
17,290
+491
+3% +$38.8K ﹤0.01% 2730
2016
Q1 		$1.34M Buy
16,799
+482
+3% +$38.1K ﹤0.01% 2618
2015
Q4 		$1.23M Buy
16,317
+7,128
+78% +$1.14M ﹤0.01% 2743
2015
Q3 		$3.52M Buy
9,189
+7,001
+320% +$3.16M ﹤0.01% 2060
2015
Q2 		$907K Buy
2,188
+345
+19% +$144K ﹤0.01% 3026
2015
Q1 		$875K Sell
1,843
-1,764
-49% -$837K ﹤0.01% 2947
2014
Q4 		$1.33M Buy
3,607
+18
+0.5% +$4.64K ﹤0.01% 2998
2014
Q3 		$845K Buy
+3,589
New +$813K ﹤0.01% 3148

Other funds holding LRMR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
NLP
Next Level Private Harrison, New York $511M AUM 30.94% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Deutsche Bank's LRMR Position: Q2 2026 in Review

Deutsche Bank increased its Larimar Therapeutics (LRMR) stake by 3.5% in Q2 2026, buying an estimated $13.1K and bringing the position to 96,423 shares worth $294K. The position accounts for ﹤0.01% of the portfolio, ranked #3048.

Deutsche Bank first reported a position in LRMR in Q3 2014 and has held it in 35 quarters since. The position peaked at $3.52M in Q3 2015. 46 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Deutsche Bank held 96,423 shares of Larimar Therapeutics worth $294K as of Q2 2026.
  • Deutsche Bank bought 3,291 Larimar Therapeutics shares in Q2 2026, an estimated $13.1K.
  • Larimar Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #3048 holding.
  • Deutsche Bank first reported a position in Larimar Therapeutics in Q3 2014 and has held it in 35 quarters since.
  • Deutsche Bank's Larimar Therapeutics position peaked at $3.52M in Q3 2015.
  • 46 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.